NewAmsterdam Pharma (NAMS) director receives RSUs and 15,300 share options

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp reported new equity awards. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration and scheduled to vest in full on the one-year anniversary of the vesting start date, subject to continued service. She also received an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, with all option shares vesting on January 2, 2027, also conditioned on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van der Kamp Hilde Johanna

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/07/2026		A		3,400(1)	A	(2)	10,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$35.45	01/07/2026		A		15,300		(3)	01/07/2036	Ordinary Shares	15,300	$0.00	15,300	D

Explanation of Responses:

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

2. Each RSU was granted on January 7, 2026 for no consideration.

3. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

	/s/ Louise Kooij by Power of Attorney from Hilde Johanna van der Kamp	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did NewAmsterdam Pharma (NAMS) report on this Form 4?

The filing reports that director Hilde Johanna van der Kamp received 3,400 RSUs and an option for 15,300 ordinary shares of NewAmsterdam Pharma Co N.V. on January 7, 2026.

How many restricted stock units were granted to the NewAmsterdam Pharma director?

The director was granted 3,400 restricted stock units (RSUs), each representing a contingent right to receive one ordinary share of NewAmsterdam Pharma Co N.V.

When do the RSUs granted to the NewAmsterdam Pharma director vest?

All of the 3,400 RSUs will vest on the one-year anniversary of the vesting start date, subject to the director’s continued service through that date.

What stock option grant was reported for the NewAmsterdam Pharma director?

The filing shows an option (right to buy) covering 15,300 ordinary shares with an exercise price of $35.45 per share, granted on January 7, 2026.

When will the stock options for NewAmsterdam Pharma shares vest?

All ordinary shares underlying the option, totaling 15,300 shares, will vest on January 2, 2027, the one-year anniversary of the vesting start date, if the director continues in service.

Were the RSUs granted to the NewAmsterdam Pharma director purchased for cash?

No. The Form 4 states that each RSU was granted on January 7, 2026 for no consideration, meaning there was no purchase price paid for the RSUs.

Is the NewAmsterdam Pharma reporting person a director or officer?

The reporting person, Hilde Johanna van der Kamp, is identified as a director of NewAmsterdam Pharma Co N.V. and is not listed as an officer or 10% owner in this filing.